Chronoscale Holdings Corp quarterly report, Q3 FY2018

Ekso Bionics Holdings, Inc. — Q3 2018 Form 10-Q

Reporting period: Three and nine months ended September 30, 2018. The filing identifies the registrant as Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), not Chronoscale Holdings Corp., as stated in the request metadata.

Business context

Ekso designs, develops and sells exoskeletons for medical rehabilitation and industrial use, including Ekso GT, EksoVest and EksoZeroG. The company remains in an early commercialization stage and has incurred recurring losses and negative operating cash flows.

Financial performance

MetricQ3 2018Q3 2017Nine months 2018Nine months 2017
Revenue$2.55 million$1.60 million$8.04 million$4.90 million
Gross profit$1.08 million$0.54 million$2.82 million$1.29 million
Gross margin42.5%34.1%35.1%26.4%
Operating loss$6.09 million$7.07 million$21.89 million$23.67 million
Net loss$6.98 million$6.34 million$22.86 million$20.14 million
Basic and diluted loss per share$0.11$0.18$0.38$0.73

Revenue growth reflected higher medical and industrial device sales and medical-device rentals. Management attributed improved gross profit primarily to higher medical-device selling prices in Q3 and to higher volume and prices over nine months. Q3 operating expenses fell 6%, but nine-month operating expenses were nearly flat: lower R&D spending was offset by increases in sales and marketing and general and administrative costs.

Net loss increased year over year despite improved operating results, principally because warrant revaluation produced a loss in 2018 versus a substantial gain in 2017. The nine-month comparison was also affected by the prior-year warrant gain and warrant-repurchase loss. Loss per share was lower in 2018, alongside a substantially higher weighted-average share count.

Cash, debt and liquidity

  • Cash was $13.0 million at September 30, 2018, down from $27.8 million at year-end 2017; working-capital assets totaled $19.9 million and current liabilities $10.2 million.
  • Operating cash use was $17.0 million for the first nine months, versus $25.6 million in 2017. Investing cash use was $0.1 million; financing provided $2.4 million, including $4.0 million net proceeds from ATM share sales, offset partly by $1.6 million of term-loan principal payments.
  • Debt carrying value was $5.5 million, including $2.3 million current and $3.2 million long-term. The term loan bears interest at 30-day LIBOR plus 5.41%, has a stated maturity of January 2021, and is secured by substantially all assets other than intellectual property itself.
  • The loan covenant required $6.38 million of unrestricted cash at the latest measurement. The company reported compliance at quarter-end and estimated effective unrestricted cash of $6.62 million.
  • Contractual obligations totaled $10.4 million, including term-loan payments, operating leases, purchase obligations and capital-lease obligations.

Changes, outlook and risks

  • Nine-month revenue rose 64%, while gross profit more than doubled. Medical-device revenue increased $2.5 million and industrial-device revenue increased $0.6 million compared with 2017.
  • Management said current resources were expected to cover obligations into the first quarter of 2019, but cash was not forecast to fund operations for the next 12 months from issuance of the statements. The filing therefore states that substantial doubt exists about the company’s ability to continue as a going concern.
  • Ekso said it would require significant additional financing and was pursuing equity or debt financing, collaborations or warrant solicitations. It cautioned that funding may not be available on acceptable terms, or at all; equity issuance could dilute shareholders. Without financing, it might substantially cut discretionary costs or curtail operations. The company had up to approximately $20.7 million remaining available under its $25 million ATM program at quarter-end.
  • Management planned continued investment in clinical and sales initiatives, rehabilitation-product development and industrial exoskeleton commercialization. The filing provides no quantitative revenue or earnings guidance.
  • Notable costs included severance and stock-based compensation associated with senior-management departures; a charge for an abandoned German sales-office lease; and increased sales and marketing spending year to date. Management attributed lower R&D expense to reduced headcount.
  • Clinical adoption, regulatory compliance, reimbursement, long and variable sales cycles, competition, manufacturing and supplier risks, foreign exchange exposure, and access to capital are among the stated business risks. The filing also describes shareholder derivative litigation alleging fiduciary-duty breaches related to internal controls; management considered the claims without merit and planned to defend them.
  • Management concluded disclosure controls were effective at quarter-end and reported no material quarterly change in internal control over financial reporting. The filing also describes efforts to strengthen controls after a previously reported material weakness.

Important facts for investors to verify

  • Whether the company obtained sufficient financing after the stated expected runway into Q1 2019, and the dilution or covenants associated with any financing.
  • Actual cash burn, unrestricted cash available under the monthly loan covenant, and progress toward debt payments.
  • Whether device sales, rentals and gross-margin improvement continued, particularly across medical and industrial segments.
  • Progress and results of clinical studies, customer adoption, regulatory status and any product-safety or recall developments.
  • Developments in the derivative and securities litigation, and the status of internal-control remediation.
  • The registrant identity discrepancy in the request metadata: this filing is for Ekso Bionics Holdings, Inc.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.